Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control

DSpace/Manakin Repository

Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control
 
Tremblay, Johanne; Haloui, Mounsif; Attaoua, Redha; Tahir, Ramzan; Hishmih, Camil; Harvey, François; Marois-Blanchet, François Christophe; Long, Carole; Simon, Paul; Santucci, Lara; Hizel, Candan; Chalmers, John; Marre, Michel; Harrap, Stephen; Cífková, Renata; Krajčoviechová, Alena; Matthews, David R.; Williams, Bryan; Poulter, Neil; Zoungas, Sophia; Colagiuri, Stephen; Mancia, Giuseppe; Grobbee, Diederick E.; Rodgers, Anthony; Liu, Liusheng; Agbessi, Mawussé; Bruat, Vanessa; Favé, Marie Julie; Harwood, Michelle P.; Awadalla, Philip; Woodward, Mark; Hussin, Julie G.; Hamet, Pavel
(2021) Diabetologia, volume 64, issue 9, pp. 2012 - 2025
(Article)
Abstract
Aims/hypothesis: Type 2 diabetes increases the risk of cardiovascular and renal complications, but early risk prediction could lead to timely intervention and better outcomes. Genetic information can be used to enable early detection of risk. Methods: We developed a multi-polygenic risk score (multiPRS) that combines ten weighted PRSs (10 wPRS) ... read more
Download/Full Text
Open Access version via Utrecht University Repository Publisher version
Version on publisher website for UU-students and staff
Version on publisher website
 
Keywords: ADVANCE trial, Cardiovascular complications, Genetics, Polygenic risk score, Prediction, Renal complications, UK Biobank, Internal Medicine, Endocrinology, Diabetes and Metabolism
DOI: https://doi.org/10.1007/s00125-021-05491-7
ISSN: 0012-186X
Publisher: Springer-Verlag
Note: Funding Information: This work was supported by Genome Québec, Canadian Institutes of Health Research (CIHR), Ministère de l’Économie et de l’Innovation du Québec (MEIE), Consortium Québécois sur la Découverte du Médicament (CQDM), OPTITHERA, Servier and Canada Research Chair in Predictive Genomics to PH. JH is a Fonds la Recherche du Québec en Santé (FRQS) Junior 1 Research Scholar supported by the Institute for Data Valorization (IVADO) and Fondation de l’Institut de Cardiologie de Montréal (FICM). This research has been conducted using data from UK Biobank, a major biomedical database: www.ukbiobank.ac.uk . The study funders were not involved in the design of the study; the collection, analysis, and interpretation of data; writing the report; and did not impose any restrictions regarding the publication of the report. Funding Information: JT and PH report grants from Servier and OPTITHERA during the conduct of the study and have a patent (number 62/685.642) applied for on 15 June 2018, N/Réf.: 019231-0002, licensed to OPTITHERA. JC reports grants and personal fees from Servier during the conduct of the study and grants from Idorsia outside the submitted work. MM reports personal fees from Servier, Novo Nordisk, Merck Sharp & Dohme outside the submitted work. MM is the president of a not-for-profit French Foundation entitled Fondation Francophone pour la Recherche sur le Diabète. He receives no personal fee for this function, but this foundation receives grants from the Association Française des Diabétiques and from Sanofi, Eli Lilly, Novo Nordisk, Merck Sharp & Dohme, Roche and Abbott. BW reports personal fees from Servier, Daiichi Sankyo, Boehringer Ingelheim and Novartis outside the submitted work. NP has received personal speaker fees from Servier, Takeda and Novo Nordisk, and advisory board activities from AstraZeneca and Novo Nordisk, and has received grants for his research group relating to diabetes mellitus from Diabetes UK, NIHR Efficacy and Mechanism Evaluation Programme (EME), Julius Clinical and the British Heart Foundation with a pending grant from Novo Nordisk. NP holds no stocks or shares in any such companies. SZ reports fees from Sanofi, AstraZeneca, Novo Nordisk and MSD Australia outside the submitted work. GM reports personal fees from Boehringer Ingelheim, Daiichi Sankyo, Ferrer, MEDTRONIC, Menarini International, Merck, Novartis, Recordati and Servier outside the submitted work. AR is one of the inventors on several patents filed by The George Institute for Global Health on Compositions for the Treatment of Hypertension. None of the inventors have a financial interest in these planned products. He is seconded to work for George Health Enterprises (the social enterprise arm of The George Institute for Global Health). He has received investment to develop fixed-dose combination products containing aspirin, statin and BP-lowering drugs. AR sits on a Data and Safety Monitoring Board for Idorsia. MW reports personal fees from Amgen and Kirin outside the submitted work. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. Funding Information: We thank J.-L. Chiasson, Honorary Professor of Medicine at Universit? de Montr?al for his insightful comments on the manuscript. We also thank M.-R. Guertin and P. Dumas (CRCHUM and Medpharmgene, Montreal, Qu?bec, Canada) for their clinical and organisational assistance with the ADVANCE and CLINPRADIA studies. JT and PH report grants from Servier and OPTITHERA during the conduct of the study and have a patent (number 62/685.642) applied for on 15 June 2018, N/R?f.: 019231-0002, licensed to OPTITHERA. JC reports grants and personal fees from Servier during the conduct of the study and grants from Idorsia outside the submitted work. MM reports personal fees from Servier, Novo Nordisk, Merck Sharp & Dohme outside the submitted work. MM is the president of a not-for-profit French Foundation entitled Fondation Francophone pour la Recherche sur le Diab?te. He receives no personal fee for this function, but this foundation receives grants from the Association Fran?aise des Diab?tiques and from Sanofi, Eli Lilly, Novo Nordisk, Merck Sharp & Dohme, Roche and Abbott. BW reports personal fees from Servier, Daiichi Sankyo, Boehringer Ingelheim and Novartis outside the submitted work. NP has received personal speaker fees from Servier, Takeda and Novo Nordisk, and advisory board activities from AstraZeneca and Novo Nordisk, and has received grants for his research group relating to diabetes mellitus from Diabetes UK, NIHR Efficacy and Mechanism Evaluation Programme (EME), Julius Clinical and the British Heart Foundation with a pending grant from Novo Nordisk. NP holds no stocks or shares in any such companies. SZ reports fees from Sanofi, AstraZeneca, Novo Nordisk and MSD Australia outside the submitted work. GM reports personal fees from Boehringer Ingelheim, Daiichi Sankyo, Ferrer, MEDTRONIC, Menarini International, Merck, Novartis, Recordati and Servier outside the submitted work. AR is one of the inventors on several patents filed by The George Institute for Global Health on Compositions for the Treatment of Hypertension. None of the inventors have a financial interest in these planned products. He is seconded to work for George Health Enterprises (the social enterprise arm of The George Institute for Global Health). He has received investment to develop fixed-dose combination products containing aspirin, statin and BP-lowering drugs. AR sits on a Data and Safety Monitoring Board for Idorsia. MW reports personal fees from Amgen and Kirin outside the submitted work. All other authors declare that there are no relationships or activities that might bias, or be perceived to bias, their work. Publisher Copyright: © 2021, The Author(s).
(Peer reviewed)